Subscribe

Heidelberg Pharma AG (HPHA.DE)

EUR2.55 -0.05 (-1.92%)
DE XETRA Healthcare Biotechnology
Address Gregor-Mendel-Strasse 22 68526
Ladenburg, BW, DE
CEO Dongzhou Liu
Website heidelberg-pharma.com
IPO 2006-11-13
ISIN DE000A11QVV0

Explore sections of this company profile

Description

Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR2.55 -0.05 (-1.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.7K
Beta
0.77
Float Shares
9.82M
Free Float %
21.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.74% -4.64% -5.99% -11.30% -8.25% +6.80% -21.01% -30.65% -60.50% +53.45% -95.01%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.55
DCF (Unlevered) 0.19 -92.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-19.37
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -78.7% Q1'26: +138.7% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -116.7% Q1'26: +30.8% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -3,133.4% Q1'26: -206.3% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -3,255.4% Q1'26: -141.0% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: +70.3% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +0.1% ★ Q1'26: +1.9% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.03× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.74) × ERP
WACC = 99% × Ke + 1% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.19 Current price: 2.55
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Nov 2009
actual 		Nov 2010
actual 		Nov 2011
actual 		Nov 2012
actual 		Nov 2013
actual 		Nov 2014
actual 		Nov 2015
actual 		Nov 2016
actual 		Nov 2017
actual 		Nov 2018
actual 		Nov 2019
actual 		Nov 2020
actual 		Nov 2021
actual 		Nov 2022
actual 		Nov 2023
actual 		Nov 2024
actual 		Nov 2025
actual 		Nov 2026
2 Rev. Ana.
1 EPS Ana. 		Nov 2027
2 Rev. Ana.
1 EPS Ana.
Revenue
10.00M
est: 13.18M (-24.1%)
—
est: 7.24M (-100.0%)
9.88M
est: 11.07M (-10.8%)
17.84M
est: 16.85M (+5.9%)
13.32M
est: 14.46M (-7.9%)
3.60M
est: 3.79M (-5.1%)
2.28M
est: 3.50M (-34.7%)
1.36M
est: 3.92M (-65.3%)
1.90M
est: 2.50M (-24.0%)
3.67M
est: 4.00M (-8.3%)
7.31M
est: 8.50M (-14.0%)
8.49M
est: 9.40M (-9.7%)
1.75M
est: 2.31M (-24.3%)
18.51M
est: 19.40M (-4.6%)
9.86M
est: 9.05M (+8.9%)
6.85M
est: 11.50M (-40.4%)
1.46M
est: 7.80M (-81.3%)
12.90M
11.27M – 14.53M
+65.4% YoY
26.60M
17.46M – 35.74M
+106.2% YoY
EBITDA
-12.47M
est: -12.85M (+2.9%)
-22.87M
est: -3.41M (-571.7%)
-12.86M
est: -5.15M (-149.8%)
-8.21M
est: -15.94M (+48.5%)
-3.16M
est: -13.46M (+76.5%)
-5.09M
est: -3.59M (-41.7%)
-6.20M
est: -3.36M (-84.4%)
-6.08M
est: -3.82M (-59.0%)
-10.35M
est: -5.26M (-96.9%)
-11.72M
est: -10.46M (-12.0%)
-9.60M
est: -29.33M (+67.3%)
-17.55M
est: -10.13M (-73.3%)
-24.83M
est: -14.78M (-68.0%)
-16.19M
est: -17.89M (+9.5%)
-18.71M
est: -8.82M (-112.0%)
-18.37M
est: -31.75M (+42.2%)
-44.63M
est: -7.60M (-486.9%)
-12.58M
-14.17M – -10.98M
-65.4% YoY
-25.93M
-34.84M – -17.03M
-106.2% YoY
EBIT
-12.71M
est: -12.95M (+1.9%)
-23.09M
est: -3.58M (-545.1%)
-13.38M
est: -5.41M (-147.3%)
-8.88M
est: -16.76M (+47.0%)
-4.88M
est: -14.15M (+65.5%)
-5.49M
est: -3.77M (-45.5%)
-6.51M
est: -3.53M (-84.3%)
-6.36M
est: -7.26M (+12.4%)
-10.75M
est: -5.46M (-96.8%)
-12.06M
est: -10.43M (-15.6%)
-10.14M
est: -30.29M (+66.5%)
-18.28M
est: -10.70M (-70.8%)
-25.64M
est: -15.62M (-64.2%)
-16.95M
est: -18.91M (+10.4%)
-19.58M
est: -8.90M (-120.1%)
-19.24M
est: -33.56M (+42.7%)
-47.44M
est: -7.67M (-518.7%)
-12.68M
-14.29M – -11.08M
-65.4% YoY
-26.15M
-35.13M – -17.17M
-106.2% YoY
Net Income
-12.73M
est: -155.89M (+91.8%)
-23.09M
est: -3.60M (-541.6%)
-13.93M
est: -5.44M (-156.0%)
-9.39M
est: -16.85M (+44.3%)
-5.04M
est: -14.22M (+64.6%)
-5.70M
est: -3.79M (-50.3%)
-6.55M
est: -3.55M (-84.4%)
-6.39M
est: -27.57M (+76.8%)
-10.97M
est: -5.49M (-99.9%)
-11.67M
est: -10.64M (-9.7%)
-10.15M
est: -30.29M (+66.5%)
-18.37M
est: -10.71M (-71.6%)
-26.63M
est: -15.63M (-70.4%)
-19.70M
est: -18.92M (-4.2%)
-20.35M
est: -18.47M (-10.1%)
-19.38M
est: -22.64M (+14.4%)
-42.28M
est: -28.93M (-46.1%)
-2.80M
-5.02M – -579.9K
+90.3% YoY
4.67M
-2.32M – 11.65M
+266.7% YoY
SGA
4.05M
est: 13.37M (-69.7%)
4.72M
est: 2.48M (+90.5%)
5.29M
est: 3.75M (+41.2%)
4.86M
est: 11.60M (-58.2%)
7.96M
est: 9.79M (-18.7%)
3.66M
est: 2.61M (+40.1%)
4.85M
est: 2.45M (+98.3%)
2.18M
est: 3.98M (-45.3%)
2.75M
est: 1.68M (+63.7%)
3.16M
est: 2.67M (+18.5%)
3.43M
est: 7.70M (-55.5%)
3.97M
est: 3.32M (+19.7%)
4.48M
est: 2.34M (+91.2%)
5.99M
est: 5.86M (+2.1%)
5.25M
est: 9.18M (-42.8%)
8.13M
est: 15.39M (-47.2%)
7.16M
est: 14.85M (-51.8%)
24.56M
21.45M – 27.67M
+65.4% YoY
50.64M
33.25M – 68.03M
+106.2% YoY
EPS
-3.55
est: -3.34 (-6.1%)
-5.13
est: -5.97 (+14.0%)
-0.49
est: -2.93 (+83.3%)
-1.37
est: -1.51 (+9.5%)
-0.61
est: -0.73 (+16.7%)
-0.66
est: -0.51 (-29.2%)
-0.75
est: -0.58 (-29.1%)
-0.22
est: -0.59 (+62.8%)
-0.76
est: -0.58 (-31.5%)
-0.41
est: -0.39 (-3.9%)
-0.36
est: -0.31 (-18.0%)
-0.61
est: -0.54 (-13.4%)
-0.82
est: -0.72 (-13.6%)
-0.53
est: -0.47 (-12.8%)
-0.44
est: -0.40 (-11.0%)
-0.42
est: -0.39 (-7.7%)
-0.91
est: -0.62 (-46.8%)
-0.06
-0.11 – -0.01
+90.3% YoY
0.10
-0.05 – 0.25
+266.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-26 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-25 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-19 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-18 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-15 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-14 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-30.73M
OE per share TTM
-0.65
Owner's Yield
-24.23%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
39.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-4.5K
Shares Outstanding
46.78M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Dongzhou Liu CEO & Chairman of Executive Management Board 323.8K —
Walter Miller Chief Financial Officer, MD & Member of Executive Board 316.0K male
Andras Strassz Chief Medical Officer — —
Peter Willinger Chief Financial Officer — male
Sylvia Wimmer Director of Corporate Communications — —
Jorg Kemkowski Chief Operating Officer — —
George Octavian Badescu Chief Business Officer — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology